At two upcoming events, experts will offer practical solutions to key challenges for oncology and rare disease clinical trials.

Johnson & Johnson has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a deal valued at $3.05bn in cash.

Merus and Halozyme have signed a worldwide non-exclusive partnership and licence agreement for subcutaneous formulation of petosemtamab.

In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of capital.

The fund will participate in follow-on and initial rounds, focusing on biotech and medtech ventures across core markets.

Sarepta has received US FDA approval for updated prescribing information for Elevidys, an AAV-based gene transfer therapy.

A CHMP panel has recommended the high-dose version’s approval, countering an FDA rejection for the drug in recent months.

The FDA’s verdict on Poherdy comes amid Perjeta creator Genentech’s patent infringement lawsuit against Organon and Shanghai Henlius Biotech.

Medicxi will use the €500m kitty to continue supporting drug hunters and entrepreneurs in creating asset-focused biotechnology companies. The firm will also consider assisting existing companies no ...

The US Food and Drug Administration (FDA) has a new chief drug regulator, with industry veteran Dr Richard Pazdur taking the helm amid a period of senior leadership instability at the agency. Pazdur, ...

Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for market share.

Eisai and Biogen have announced UK MHRA approval for Leqembi for intravenous (IV) maintenance dosing to treat early Alzheimer's.